Lisa Cupit

1.1k total citations
15 papers, 891 citations indexed

About

Lisa Cupit is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lisa Cupit has authored 15 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Lisa Cupit's work include Colorectal Cancer Treatments and Studies (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Lisa Cupit is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Lisa Cupit collaborates with scholars based in United States, Germany and Italy. Lisa Cupit's co-authors include Frank Cihon, Martin Reck, U. Gatzemeier, George R. Blumenschein, Frank V. Fossella, David J. Stewart, James J. O’Leary, Joachim von Pawel, Beatrix Bálint and Carlos H. Barrios and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Lisa Cupit

14 papers receiving 881 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Cupit United States	9	647	462	404	217	113	15	891
Hirokazu Ogino Japan	15	580 0.9×	551 1.2×	521 1.3×	158 0.7×	127 1.1×	54	1.1k
Osvaldo Rudy Aren Chile	12	647 1.0×	489 1.1×	310 0.8×	189 0.9×	69 0.6×	22	841
Beata Korytowsky United States	17	617 1.0×	565 1.2×	370 0.9×	250 1.2×	62 0.5×	78	1.1k
Olga Valota Italy	14	563 0.9×	346 0.7×	436 1.1×	258 1.2×	81 0.7×	43	891
Robert C. Whorf United States	10	477 0.7×	418 0.9×	346 0.9×	200 0.9×	49 0.4×	20	790
Hilary Glen United Kingdom	13	845 1.3×	475 1.0×	668 1.7×	453 2.1×	99 0.9×	34	1.3k
Yoshiko Umeyama Japan	16	554 0.9×	490 1.1×	263 0.7×	146 0.7×	111 1.0×	35	813
Tsveta Milenkova United Kingdom	15	906 1.4×	1.0k 2.2×	467 1.2×	546 2.5×	79 0.7×	32	1.5k
Oana Petrenciuc United States	16	1.0k 1.6×	779 1.7×	552 1.4×	335 1.5×	81 0.7×	36	1.6k
Yifah Yaron United States	11	382 0.6×	615 1.3×	336 0.8×	149 0.7×	108 1.0×	17	1.4k

Countries citing papers authored by Lisa Cupit

Since Specialization

Citations

This map shows the geographic impact of Lisa Cupit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Cupit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Cupit more than expected).

Fields of papers citing papers by Lisa Cupit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Cupit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Cupit. The network helps show where Lisa Cupit may publish in the future.

Co-authorship network of co-authors of Lisa Cupit

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Cupit. A scholar is included among the top collaborators of Lisa Cupit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Cupit. Lisa Cupit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Adjei, Alex A., Tanios Bekaii‐Saab, Jordan Berlin, et al.. (2018). Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.. Journal of Clinical Oncology. 36(15_suppl). TPS2607–TPS2607. 10 indexed citations

Adjei, Alex A., Annette O. Walter, Lisa Cupit, et al.. (2017). Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. Annals of Oncology. 28. v141–v141. 2 indexed citations

Dreyling, Martin, Armando Santoro, Sirpa Leppä, et al.. (2017). Copanlisib in patients with relapsed or refractory follicular lymphoma.. Journal of Clinical Oncology. 35(15_suppl). 7535–7535. 4 indexed citations

Nowakowski, Grzegorz S., Igor Gorbatchevsky, Florian Hiemeyer, Lisa Cupit, & Barrett H. Childs. (2016). Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2. Cancer Research. 76(14_Supplement). CT084–CT084. 1 indexed citations

Dreyling, Martin, et al.. (2015). Abstract CT215: CHRONOS-1: Open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL). Cancer Research. 75(15_Supplement). CT215–CT215.

Nowakowski, Grzegorz S., Igor Gorbatchevsky, Florian Hiemeyer, Lisa Cupit, & Barrett H. Childs. (2015). Abstract CT212: CHRONOS-2: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL). Cancer Research. 75(15_Supplement). CT212–CT212. 6 indexed citations

Grothey, Axel, Alberto Sobrero, Salvatore Siena, et al.. (2013). Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.. Journal of Clinical Oncology. 31(15_suppl). 3637–3637. 27 indexed citations

Grothey, Axel, Eric Van Cutsem, Alberto Sobrero, et al.. (2013). Time course of regorafenib-associated adverse events in the phase III CORRECT study.. Journal of Clinical Oncology. 31(4_suppl). 467–467. 24 indexed citations

Cutsem, Eric Van, Alberto F. Sobrero, Salvatore Siena, et al.. (2013). Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.. Journal of Clinical Oncology. 31(15_suppl). 3636–3636. 16 indexed citations

10.

Grothey, Axel, Salvatore Siena, Alfredo Falcone, et al.. (2012). Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update. Annals of Oncology. 23. ixe10–ixe10. 3 indexed citations

11.

Bukowski, Ronald M., Walter M. Stadler, David F. McDermott, et al.. (2010). Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology. 78(5-6). 340–347. 33 indexed citations

12.

Stadler, Walter M., Robert A. Figlin, David F. McDermott, et al.. (2010). Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 116(5). 1272–1280. 193 indexed citations

13.

Scagliotti, Giorgio V., Silvia Novello, Joachim von Pawel, et al.. (2010). Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(11). 1835–1842. 365 indexed citations

14.

Pacey, Simon, Mark J. Ratain, Keith T. Flaherty, et al.. (2009). Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs. 29(3). 481–488. 40 indexed citations

15.

Blumenschein, George R., U. Gatzemeier, Frank V. Fossella, et al.. (2009). Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(26). 4274–4280. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact